Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$112.51NASDAQ Previous Close - Last Trade as of 4:15PM ET 1/16/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$110.60 (2)
Ask (Size)$113.00 (10)
Day Low / HighN/A - N/A
Volume1.4 M

View Biotechnology IndustryPeer Comparison as of 01/16/2020


Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $112.51
Change: -0.02 (0.02%)
Volume: 1.4 M
4:15PM ET 1/16/2020

Agilent Technologies Inc ( NYSE )

Price: $89.46
Change: +0.84 (0.95%)
Volume: 1.6 M
6:30PM ET 1/16/2020

Seattle Genetics Inc ( NASDAQ )

Price: $107.66
Change: +1.01 (0.95%)
Volume: 1.0 M
4:00PM ET 1/16/2020

Incyte Corp ( NASDAQ )

Price: $80.62
Change: +0.08 (0.10%)
Volume: 1.3 M
4:00PM ET 1/16/2020

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $89.13
Change: +0.26 (0.29%)
Volume: 1.1 M
4:00PM ET 1/16/2020

Read more news Recent News

Alexion Pharmaceuticals Planning Phase 3 Study of ALS Drug Ultomiris
9:28AM ET 1/14/2020 MT Newswires

Alexion Pharmaceuticals (ALXN) said pre-market Tuesday that it plans to conduct a phase 3 trial of Ultomiris for the treatment of amyotrophic lateral...

OPTIONS: Option Implied Volatility for Healthcare
5:15AM ET 12/31/2019 MT Newswires

Option implied volatility for Healthcare Alexion Pharmaceuticals (ALXN) 30-day option implied volatility is at 35; compared with its 52-week range of 29 to...

Achillion Shareholders Back $930 Million Acquisition by Alexion
10:37AM ET 12/19/2019 MT Newswires

Achillion Pharmaceuticals (ACHN) said Thursday that about 99% of its shareholders voted in support of the company's $930 million acquisition by Alexion...

Analyst Actions: Morgan Stanley Downgrades Alexion Pharmaceuticals to Equal-Weight From Overweight
7:13AM ET 12/17/2019 MT Newswires

Alexion Pharmaceuticals' (ALXN) average rating among analysts is a buy, with an average price target of $157. Price: 111.37, Change: +0.95, Percent Change:...

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Number of Employees2,656
Recent SEC Filing01/13/20208-K
Chief Executive Officer & DirectorLudwig N. Hantson
Chief Commercial, Global Operations Officer & EVPBrian M. Goff
Chief Financial Officer & Executive Vice PresidentAradhana Sarin
Executive VP, Head-Research & DevelopmentJohn J. Orloff

Company Highlights

Price Open$113.51
Previous Close$112.51
52 Week Range$94.59 - 141.86
Market Capitalization$24.9 B
Shares Outstanding221.3 M
SectorHealth Technology
Next Earnings Announcement02/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings16.77
Earnings per Share$7.79
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin31.29%
Return on Equity14.93%

Analyst Ratings as of 12/17/2019

Consensus RecommendationConsensus Icon
Powered by Factset